Research findings change misconception on white blood cell trafficking to spleen

Contrary to prior belief, the white blood cells enter the spleen primarily via vessels in the red pulp. The research results change thoroughly our perception of the spleen producing antibodies vital for the human body.

Spleen is our largest lymphoid organ. Its function is to eliminate outdated red blood cells and to produce antibodies against pathogens. Outdated red blood cells are eliminated in the spleen's red pulp and antibodies are produced in the white pulp.

The significance of the spleen for the production of antibodies is central, as removing the spleen predisposes the patient to certain microbe infections.

So far, white blood cells have been believed to enter the spleen from the circulation through the marginal zone surrounding the white pulp. However, no molecule controlling white blood cell trafficking has been identified in any of the laboratories working in the trafficking field in spite of three decades of research.

Contrary to prior belief, the research groups at University of Turku in Finland led by Academy Research Fellow Maija Hollmén and Academician of Science, Professor of Immunology Sirpa Jalkanen together with their collaborators have been able to show that white blood cells enter the spleen primarily via vessels in the red pulp and are then migrating to the other structures of the spleen.

Additionally, the researchers were able to confirm that the Clever-1 (Common Lymphatic and Vascular Endothelial Receptor-1) molecule found by the group earlier controls white blood cell trafficking to both mouse and human spleen.

- White blood cells entering the spleen directly attach to the Clever-1 molecule on the vessel wall. In addition, Clever-1 controls expression of other trafficking-associated molecules produced by the vessel. Such a molecule is for example the attractant for antibody-producing white blood cells, says Hollmén.

- The research results change our perception of the spleen all the way to the textbook level. It is possible that the immune responses taking place in the spleen could be controlled by suppressing or activating the Clever-1 molecule in the future, adds Jalkanen.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered MRI predicts outcomes in prostate cancer